Open tender · Germany · Pharmaceutical products
Open-House-Biologika-Rabattverträge 2026-11 - Infliximab (Darreichungsform zur intravenösen Anwendung)
In EnglishOpen House biological discount contracts 2026-11 - Infliximab (formulation for intravenous use)
Techniker Krankenkasse in Germany is inviting bids for “Open House biological discount contracts 2026-11 - Infliximab (formulation for intravenous use)”. Bids close on 31 May 2028, 23:58 CEST. askTender lists every requirement to qualify and checks whether your company meets them.
The work
Schluss von Rabattverträgen nach § 130a Abs. 8 SGB V zu Infliximab im Rahmen eines Open-House-Verfahrens mit maximal 24 Monate Laufzeit beginnend am 01.06.2026.
Key facts
- Procedure
- Contract notice
Before you bid, askTender
Everything else is in your askTender account
askTender has broken this tender down into 6 requirements to qualify (6 on experience) and the 1 document a bidder must file.
- What it takes to qualify: every requirement, in the tender’s own words
- Whether your company qualifies: your profile checked against each requirement, showing what you have, what’s missing and how to close the gap
- The documents to file: a checklist, with draft declarations ready to sign
- A bid partner for any requirement you can’t meet alone
- The tender documents, ready to open
- Alerts for new tenders like this one
Public data: TED – Tenders Electronic Daily. © European Union, 1998–2026. Notices reused under Commission Decision 2011/833/EU. · Sources & licences